1. A Guide to Infection Control in the Hospital. An official publication of the International Society of Infection Diseases. 2nd ed. Ed: R.Wenzel, T.Brewer, J.-P.Brutzler. BC Decker Inc. Hamilton, London, 2002.
2. Hubmayr RD. Statement of the 4th International Consensus Conference in Critical Care in ICU-Acquired Pneumonia, Illinois, May, 2002. Intensive Care Med 2002; 28: 1521–36.
3. National Nosocomial Infections Surveillance System Report, issue October 2004. Am J Infection Control 2004; 32: 470–85.
4. Эйдельштейн М.В. Выявление бета-лактамаз расширенного спектра у грамотрицательных бактерий с помощью фенотипических методов. Клин. микробиол. антимикроб. химиотер. 2001; 2: 183–9.
5. Fagon JY, Chastre J, Hance AJ et al. Nosocomial pneumonia in ventilated patients: a cohort evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281–8.
6. Fagon JY, Chastre J, Vuagnet A et al. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275 (11): 866–9.
7. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2005.
8. Рекомендации по оптимизации антимикробной терапии нозокомиальных инфекций, вызванных грамотрицательными бактериями в отделениях реанимации и интенсивной терапии. Пособие для врачей. Клин. микробиол. антимикроб. химиотер. 2000; 4: 379–90.
9. Eggimann P, Pittet D. Infection control in ICU. Chest 2001; 120: 2053–93.
10. Розанова С.М., Руднов В.А., Бейкин Я.Б. и др. Результаты мониторинга устойчивости возбудителей госпитальных инфекций к антибиотикам в ОРИТ Екатеринбурга. Клин. микробиол. антимикроб. химиотер. 2005; 7 (4): 410–8.
11. Trouillet JL, Chastre J, Vuagnant A et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am Rev Resp Crit Care Med 1998; 157: 531–9.
12. Blackwood L, Stone R, Iglevski B et al. Evaluation P.aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect Immune 1983; 39: 198–201.
13. Woods DE, Schaffer MS, Rabin HR et al. Phenotyping comparison of P. aeruginosa strains isolated from a variety of clinical sites. J Clin Microbiol 1986; 24: 260–4.
14. Frank D. Exoenzyme S regulation of P. aeruginosa. Mol Microbiol 1997; 26: 621–9.
15. Frithz-Lindsten E, Du Y, Rosquist R et al. Intracellular targeting of exoenzyme S of P.aeruginosa via type III – dependent translocation. Mol Microbiol 1997; 25: 1125–39.
16. Kurahashi K, Kajikawa O, Sawa T et al. Pathogenesis of septic shock in P.aeruginosa pneumonia. J Clin Invest 1999; 104: 743–50.
17. Roy-Burman A, Savel RH, Racine S et al. Type III protein secretion is associated with death in lower respiratory and systemic P. aeruginosa infection. J Infect Dis 2001; 183: 1767–74.
18. Hauser AR, Cobb E, Bodi M et al. Type III protein secretion is associated with poor clinical outcomes in patients with VAP caused P.aeruginosa. Crit Care Med 2002; 30 (3): 521–8.
19. Bassler BL. Curr Opin Microbiol 1999; 2: 582–7.
20. Bertrand X, Thouverez M, Talon D et al. Endemicity, molecular diversity and colonization routes of P.aeruginosa in ICU. Intensive Care Med 2001; 27: 1263–8.
21. Carmeli Y, Troillet N, Eliopoulos GM et al. Emergence of antibiotic-resistant P. aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobiol Agents Chemother 1999; 43: 1379–82.
22. Blin F, Fraisse F, Lahilaire P. Abstracts of the 38th ICAAC 1998 San Diego S. 535.
23. Решедько Г.К., Рябкова Е.Л., Фаращук А.Н. и др. Неферментирующие грамотрицательные возбудители нозокомиальных инфекций в ОРИТ России: проблемы антибиотикорезистентности. Клин. микробиол. антимикроб. химиотер. 2006; 8 (3): 1–16.
24. Van Looveren M, Goosens H, ARPAC Steering Group (Europe). Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684–704.
25. Harris AD, Smith D, Johnson JA et al. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34: 340–5.
26. Boyce JM, Pittet D. Guideline for hand hygiene in health-care setting: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA. Infection Control and Hospital Epidemiology 2002; 23 (12): 3–34.
27. Sandiumenge А, Diaz E, Rodriguez A et al. Impact of diversity of antibiotics use on development antibiotic resistance AAC 2006; 57: 1197–204.
28. Lepper PM, Crusa E, Reichl H et al. Consuption of imipenem correlate with B-lactams resistance in P. aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920–5.
29. Руднов В.А., Фролова З.А., Розанова С.М. и др. Клиническая значимость инфекций, вызванных панрезистентными штаммами Pseudomonas aeruginosa у пациентов ОРИТ. Клин. микробиол. антимикроб. химиотер. 2007; 9 (2): 37.
30. Kumar A, Roberts D, Wood K et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in septic shock. Crit Care Med 2006; 34: 1589–96.
31. Paterson DL. The epidemiological profile of infection with multidrug-resistant P.aeruginosa and Acinetobacter species. CID 2006; 43: 43–8.
32. Falagas M, Biziotis I, Siempos I. Attributable mortality of A. Baumannii infection in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R48 (doi:10.1186/cc4869).
33. Drusano GL. Prevrntion of resistance: a goal for dose selection of antimicrobials agents. Clin Infect Dis 2003; 36: 42–52.
34. Kuti JL, Dandekar PK, Nightingale C. Use Monte Carlo Simulation to design an optimized pharmacodynamic dosing. J Clin Pharmacol 2003; 43: 1116–23.
35. Lorente P, Garsia C, Martin M et al. Continuous infusion versus intermittent infusion of ceftazidim for treatment pneumonia caused by P. aeruginosa. Crit Care 2005; 9 (S1): P39.
36. Lipman J, Gomersall CD, Gin T et al. J Antimicrob Chemother 1999; 43: 309–11.
37. Nikodemski T, Giedrys-Kalemba S, Bohatyrewicz R et al. Epidemiological impact of the antimicrobial therapy on Acinetobacter spp. isolated from ITU patients. Crit Care 1998; 2 (S1): P101.
38. Brahmi N, Biel Y, Kouraichi A et al. Evoluotion of resistance in Acinetobacter baumannii in Tunisian ICU after antibiotic therapy restriction. Crit Сare 2005; 9 (S1): P19.
39. Гончаров В.Б., Руднов В.А., Черкасов Г.В. и др. Результаты внедрения концепции инфекционной безопасности в ОРИТ нейрохирургического профиля. Интенсивн. тер. 2008; 1 (в печати).
40. Lautenbach E, Polk R. Resistant gram-negative bacilli: neglected healthcare crisis. Am J Healht-System Pharmacy 2007; 64, 23 (S14): 3–21.
41. Ibrahim E, Ward S, Sherman G. Experience with a clinical guideline for the treatment of VAP. Crit Care Med 2001; 29: 1109–15.
42. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7: 78–83.
43. Kadusevicius E, Zmuidaite V, Stankeviciene I et al. Clinical outcomes and effectiveness of antimicrobial treatment of patients with antibiotic-resistant P.aeruginosa pneumonia. Clin Microbiol Inf 2003; 9 (8): P1513.
44. Falagas M, Kasiakou S, Rafalidis P et al. Comparison of mortality of patients with Acinetobacter baumannii bacteremia receiving appropriate and inappropriate empirical therapy. JAC 2006; 57 (6): 1251–4.
45. Wickens H, Warr C, Jepson A. An outbreak of multi-drug resistant Acinetobacter baumannii Infection on an ICU, and treatment with tigecycline. Absracts. ICAAC, 2006; K-1498.
46. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей.  Под. ред. А.Г.Чучалина, А.И.Синопальникова, Л.С.Страчунского и др. 2005.
47. Hospital-acquired pneumonia guidelines committee of the ATS/IDSA. Am J Respir Crit Care Med 2005; 171: 388–414.
48. Siu D, Chan J, Dellit T. Monotherapy vs. combination antimicrobial therapy for P.aeruginosa bacteremia in era incresead fluoroquinolone use. Absracts. ICAAC, 2006; K-521.
49. Donaldson A, Razak L, Fisher P. "De-escalation" strategies in carbapenem usage do not protect against multi-drug resistant blood stream infection. Absracts. ICAAC, 2006: K-524.
50. Osih R, McCregor J, Rich S et al. Impact of empiric therapy on outcomes in pseudomonas bacteremia. Absracts. ICAAC, 2006; K-523.
51. Cortes J, Urdaneta A, Alvarez C. Outcome of bacteremia caused by Acinetobacter baumannii at an university hospital. Absracts. ICAAC, 2006; K-1503.
52. Paul M, Benuri-Silbiger I, Soares-Weiser K. Beta-lactam monotherapy versus beta-lactam aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004; 328: 668–81.
53. Dellit T, Owens R, McGowan J et al. IDSA/SHEA guidelines for developing an institutional program to enhance antimicrobial stewardship. CID 2007; 44: 159–77.
54. Joly-Guillou M.-L. Clinical impact and pathogenicity of Acinetobacter Acinetobacter spp. Clin Microbiol Infect 2005; 11: 868–73.